iC9.GD2.CAR.IL-15 T Therapy for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
Lineberger Comprehensive Cancer Center, Chapel Hill, NCNon-Small Cell Lung Cancer+2 MoreiC9.GD2.CAR.IL-15 T Infusion - Biological
All Sexes
What conditions do you have?

Study Summary

This trial is testing a combination of antibodies and T cells to treat lung cancer. It will look at how much of the treatment is safe and what dosage is the most effective.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 8 Secondary · Reporting Duration: Up to 2 years

Disialoganglioside (GD2) Expression
Up to 2 years
Duration of Benefit
Duration of Response (DOR)
Overall Survival (OS)
Progression Free Survival (PFS)
Up to 4 weeks
Cytokine Release Syndrome (CRS)
Identification of Recommended phase 2 dose (RP2D)
Number of participants with adverse event
Overall Response Rate (ORR)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

iC9.GD2.CAR.IL-15 T Therapy
1 of 1

Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: iC9.GD2.CAR.IL-15 T Therapy · No Placebo Group · Phase < 1

iC9.GD2.CAR.IL-15 T Therapy
Experimental Group · 1 Intervention: iC9.GD2.CAR.IL-15 T Infusion · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
320 Previous Clinical Trials
82,411 Total Patients Enrolled
Bellicum PharmaceuticalsIndustry Sponsor
24 Previous Clinical Trials
1,229 Total Patients Enrolled
Jared WeissPrincipal Investigatorjared_weiss@med.unc.edu

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
How many prior treatments have patients received?

Frequently Asked Questions

What is the fundamental aim of this clinical study?

"This medical trial is assessing cytokine release syndrome (CRS) for a time frame of up to 4 weeks. Secondary outcomes in this study include disialoganglioside expression, overall response rate and duration of response which will be measured using immunohistochemistry on tumor samples collected from participants according to Response Evaluation Criteria In Solid Tumors criteria. ORR is calculated by summing the number of patients that achieved complete or partial responses divided by the total number who received treatment while DOR is noted as starting with either partial or full respose to disease progression based on RECIST 1.1 metrics: CR defined as disappearance" - Anonymous Online Contributor

Unverified Answer

Are patients being recruited for this experiment currently?

"According to clinicaltrials.gov, this medical experiment is no longer enrolling candidates. It was initially listed on January 15th 2023 and its most recent update occurred in November 16th 2022. Nevertheless, 1979 other trials are actively recruiting patients at the present time." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.